Mabtas 500 mg Injection Supplier USA | Pharmaceutical Exporter from India

Mabtas 500 mg Injection: High-Dose CD20 Immunotherapy for Advanced Oncology & Autoimmune Care

Are you seeking a dependable Mabtas 500 mg injection exporter from India? Ernest Oncology, a dedicated division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of high-potency monoclonal antibodies. We manage a robust, cold-chain-integrated supply chain serving the USA, UK, Australia, and South Africa, ensuring that critical Rituximab therapies reach medical centers with 100% product integrity and streamlined international logistics.

Detailed Product Overview: What is Mabtas 500 mg?

Mabtas 500 mg Injection is a chimeric monoclonal antibody containing the active ingredient Rituximab. Manufactured by Intas Pharmaceuticals Ltd., Mabtas is a globally recognized biosimilar that offers clinical efficacy and safety equivalent to the reference product.

For international B2B procurement, the 500 mg/50 ml vial is the preferred high-dose format for induction phases and large-scale hospital requirements, providing a cost-effective solution for treating aggressive B-cell malignancies.

Primary Therapeutic Indications

Mabtas 500 mg is used globally for the following:

1. Non-Hodgkin Lymphoma (NHL): Including Follicular Lymphoma and Diffuse Large B-Cell Lymphoma (DLBCL).

2. Chronic Lymphocytic Leukemia (CLL): Combined with chemotherapy for first-line or relapsed cases.

3. Rheumatoid Arthritis (RA): For adult patients who have not responded to TNF-antagonist therapies.

4. Granulomatosis with Polyangiitis (GPA) & Microscopic Polyangiitis (MPA): Managing severe vascular inflammation.

5. Pemphigus Vulgaris (PV): Treating moderate to severe autoimmune skin blistering.

Mechanism of Action: Targeted B-Cell Destruction

Mabtas 500 mg operates through a high-precision immunological process:

• Selective CD20 Binding: Rituximab binds specifically to the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes.

• Immune System Activation: Once attached, the antibody triggers the body's immune response to eliminate target cells via:

  • Antibody-Dependent Cellular Cytotoxicity (ADCC): NK cells lyse the bound B cells.

  • Complement-Dependent Cytotoxicity (CDC): The complement system destroys cell membranes.

  • Direct Apoptosis: Signaling the cancer or autoimmune B-cells to undergo programmed cell death.

• Rapid Depletion: This leads to a significant reduction in malignant cells or auto-antibody-producing cells, halting disease progression.

Administration and Clinical Safety

• Intravenous Infusion: Mabtas 500 mg must be administered as an IV infusion by qualified medical staff. It is not for IV push or bolus.

• Standard Premedication: Patients are typically pre-treated with antipyretics (e.g., acetaminophen) and antihistamines to reduce the risk of infusion-related reactions.

• Cold-Chain Storage: Must be stored at 2°C to 8°C (36°F to 46°F). Do not freeze, shake, or expose to light.

• Safety Protocols: * HBV Screening: Hepatitis B screening is mandatory before starting therapy.

  • Monitoring: Continuous monitoring for infusion reactions, tumor lysis syndrome, and cardiac arrhythmias is required during the procedure.

Why Source Mabtas from Ernest Oncology?

• Direct Indian Exporter: Authentic inventory sourced directly from Intas Pharmaceuticals for 100% purity and competitive B2B pricing.

• Validated Cold-Chain Export: We use advanced thermal packaging to ensure Rituximab remains within the required temperature range throughout transit to the USA, UK, Australia, and South Africa.

• Global Compliance: Full B2B documentation provided, including GMP compliance certificates and batch-specific COAs.

• Bulk Supply Stability: We specialize in large-scale fulfillment for oncology centers, government tenders, and regional pharmaceutical distributors.